Aguiar Jr AS, Araujo AL, da-Cunha TR, et al (2009) Physical exercise improves motor and short-term social memory deficits in reserpinized rats. Brain Research Bulletin. https://doi.org/http://dx.doi.org/10.1016/j.brainresbull.2009.05.005
Ascherio A, Zhang SM, Hernán MA, et al (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Annals of neurology 50:56–63. https://doi.org/10.1002/ana.1052
Aurich MF, Rodrigues LS, Targa ADS, et al (2017) Olfactory impairment is related to REM sleep deprivation in rotenone model of Parkinson’s disease. Sleep Science 10:47–54. https://doi.org/10.5935/1984-0063.20170008
Bobrovskaya L, Gilligan C, Bolster EK, et al (2007) Sustained phosphorylation of tyrosine hydroxylase at serine 40: A novel mechanism for maintenance of catecholamine synthesis. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2006.04213.x
Bové J, Perier C (2012) Neurotoxin-based models of Parkinson’s disease. Neuroscience 211:51–76. https://doi.org/10.1016/j.neuroscience.2011.10.057
Braak H, Tredici K Del, Rüb U, et al (2003) Staging of Brain Pathology Related to Sporadic Parkinson ’ s Disease Staging of brain pathology related to sporadic Parkinson ’ s disease. Neurobiology of Aging 4580:197–211. https://doi.org/10.1016/S0197-4580(02)00065-9
Chioca LR, Antunes VDC, Ferro MM, et al (2013) Anosmia does not impair the anxiolytic-like effect of lavender essential oil inhalation in mice. Life Sciences 92:971–975. https://doi.org/10.1016/j.lfs.2013.03.012
Cóppola-Segovia V, Cavarsan C, Maia FG, et al (2017) ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson’s Disease. Molecular Neurobiology 54:5798–5806. https://doi.org/10.1007/s12035-016-0114-x
Dantzer R, Bluthe RM, Koob GF, Le Moal M (1987) Modulation of social memory in male rats by neurohypophyseal peptides. Psychopharmacology. https://doi.org/10.1007/BF00518192
Dos Santos ACD, Castro MA V, Jose EAK, et al (2013) REM sleep deprivation generates cognitive and neurochemical disruptions in the intranigral rotenone model of Parkinson’s disease. Journal of Neuroscience Research 91:1508–1516. https://doi.org/10.1002/jnr.23258
Doty R Lo, Applebaum S, Zusho H, Settle RG (1985) Sex Differences in Odor Identification a Cross-Cul Tural Anal Ysis Ability. 23:667–672
Doty RL (2012) Olfactory dysfunction in Parkinson disease. Nature Reviews Neurology 8:329–339. https://doi.org/10.1038/nrneurol.2012.80
Doty RL (2017) Personal View Olfactory dysfunction in neurodegenerative diseases : is there a common pathological substrate ? The Lancet Neurology 16:478–488. https://doi.org/10.1016/S1474-4422(17)30123-0
Doty RL, Cameron EL (2009) Sex differences and reproductive hormone influences on human odor perception. Physiology and Behavior
Doty RL, Deems D, Steller S (1988) Olfactory dysfunction in Parkinson’s disease: A general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38:1237–1244
Doty RL, Risser JM (1989) Influence of the D-2 dopamine receptor agonist quinpirole on the odor detection performance of rats before and after spiperone administration. Psychopharmacology 98:310–315. https://doi.org/10.1007/BF00451680
Doty RL, Stern MB, Pfeiffer C, et al (1992) Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. Journal of Neurology Neurosurgery and Psychiatry. https://doi.org/10.1136/jnnp.55.2.138
Fagotti J, Targa ADS, Rodrigues LS, et al (2019) Chronic sleep restriction in the rotenone Parkinson’s disease model in rats reveals peripheral early-phase biomarkers. Scientific Reports 9:1–16. https://doi.org/10.1038/s41598-018-37657-6
Fredholm BB, Bättig K, Holmén J, et al (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacological reviews 51:83–133. https://doi.org/0031-6997/99/5101-0083$03.00/0
Garção P, Szabõ EC, Wopereis S, et al (2013) Functional interaction between pre-synaptic α6β2-containing nicotinic and adenosine A2A receptors in the control of dopamine release in the rat striatum. British Journal of Pharmacology 169:1600–1611. https://doi.org/10.1111/bph.12234
Gutièrrez-Mecinas M, Crespo C, Blasco-Ibáñez JM, et al (2005) Distribution of D2 dopamine receptor in the olfactory glomeruli of the rat olfactory bulb. European Journal of Neuroscience 22:1357–1367. https://doi.org/10.1111/j.1460-9568.2005.04328.x
Höglinger GU, Alvarez-Fischer D, Arias-Carrión O, et al (2015) A new dopaminergic nigro-olfactory projection. Acta Neuropathologica 130:333–348. https://doi.org/10.1007/s00401-015-1451-y
Hong CT, Chan L, Bai CH (2020) The effect of caffeine on the risk and progression of parkinson’s disease: A meta-analysis. Nutrients 12:1–12. https://doi.org/10.3390/nu12061860
Hsu CW, Wang CS, Chiu TH (2010) Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice. Journal of Biomedical Science 17:. https://doi.org/10.1186/1423-0127-17-4
Ikram M, Park TJ, Ali T, Kim MO (2020) Antioxidant and neuroprotective effects of caffeine against Alzheimer’s and parkinson’s disease: Insight into the role of Nrf-2 and A2AR signaling. Antioxidants 9:1–21. https://doi.org/10.3390/antiox9090902
Ilkiw JL, Kmita LC, Targa ADS, et al (2018) Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson’s Disease. Molecular Neurobiology
Knowles PJ, Douglas SA, Bunn SJ (2011) Nicotinic Stimulation of Catecholamine Synthesis and Tyrosine Hydroxylase Phosphorylation in Cervine Adrenal Medullary Chromaffin Cells. Journal of Neuroendocrinology 23:224–231. https://doi.org/10.1111/j.1365-2826.2010.02100.x
Koster NL, Norman AB, Richtand NM, et al (1999) Olfactory Receptor Neurons Express D2 Dopamine Receptors. J Compar Neurol 411:666–673
Lane E, Dunnett S (2008) Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic? Psychopharmacology 199:303–312. https://doi.org/10.1007/s00213-007-0931-8
Lang AE, Lozano AM (1998) First of Two Parts. The New England Journal of Medicine 339:1044–53. https://doi.org/10.1056/NEJM199810083391506
Leão AHFF, Sarmento-Silva AJ, Santos JR, et al (2015) Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson’s Disease: New Perspectives to a Long-Standing Model. Brain Pathology
Liu R, Umbach DM, Peddada SD, et al (2015) Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease. Neurology 84:2107–2115. https://doi.org/10.1212/WNL.0000000000001609
Machado-Filho JA, Correia AO, Montenegro ABA, et al (2014) Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions. Behavioural Brain Research 264:116–125. https://doi.org/10.1016/j.bbr.2014.01.051
Monique SOFFIE and Yves LAMBERTY (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imagingSeparation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Птицы 1:12–17
Moreira CG, Barbiero JK, Ariza D, et al (2012) Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: A new approach for an old neurotoxin. Neurotoxicity Research 21:291–301. https://doi.org/10.1007/s12640-011-9278-3
Mouhape C, Costa G, Ferreira M, et al (2018) Nicotine-Induced Neuroprotection in Rotenone In Vivo and In Vitro Models of Parkinson’s Disease: Evidences for the Involvement of the Labile Iron Pool Level as the Underlying Mechanism. Neurotoxicity research. https://doi.org/https://dx.doi.org/10.1007/s12640-018-9931-1
Nicholatos JW, Francisco AB, Bender CA, et al (2018) Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6. Acta neuropathologica communications 6:120. https://doi.org/10.1186/s40478-018-0625-y
Noseda ACD, Rodrigues LS, Targa ADS, et al (2014) Putative role of monoamines in the antidepressant-like mechanism induced by striatal MT2 blockade. Behavioural Brain Research 275:136–145. https://doi.org/10.1016/j.bbr.2014.09.007
O’Connor S, Jacob TJC (2008) Neuropharmacology of the olfactory bulb. Current molecular pharmacology. https://doi.org/10.2174/1874467210801030181
Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates. Journal of Chemical Information and Modeling. https://doi.org/10.1017/CBO9781107415324.004
Ponsen MM, Stoffers D, Booij J, et al (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Annals of Neurology 56:173–181. https://doi.org/10.1002/ana.20160
Prediger RDS, Aguiar AS, Rojas-Mayorquin AE, et al (2010) Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson’s disease. Neurotoxicity research. https://doi.org/10.1007/s12640-009-9087-0
Prediger RDS, Batista LC, Takahashi RN (2005a) Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats: Involvement of adenosine A1and A2Areceptors. Neurobiology of Aging 26:957–964. https://doi.org/10.1016/j.neurobiolaging.2004.08.012
Prediger RDS, Fernandes D, Takahashi RN (2005b) Blockade of adenosine A2Areceptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behavioural Brain Research 159:197–205. https://doi.org/10.1016/j.bbr.2004.10.017
Remaud S, López-Juárez SA, Bolcato-Bellemin A-L, et al (2013) Inhibition of Sox2 Expression in the Adult Neural Stem Cell Niche In Vivo by Monocationic-based siRNA Delivery. Molecular Therapy - Nucleic Acids 2:e89. https://doi.org/10.1038/mtna.2013.8
Rodrigues LS, Noseda ACD, Targa ADS, et al (2018) Olfaction in female Wistar rats is influenced by dopaminergic periglomerular neurons after nigral and bulbar lesions. 1–9. https://doi.org/10.1097/FBP.0000000000000443
Rodrigues LS, Targa ADS, Noseda ACD, et al (2014) Olfactory impairment in the rotenone model of Parkinsonâ€TMs disease is associated with bulbar dopaminergic D2 activity after REM sleep deprivation. Frontiers in Cellular Neuroscience 8:1–11. https://doi.org/10.3389/fncel.2014.00383
Ross GW, Petrovitch H, Abbott RD, et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Annals of Neurology 63:167–173. https://doi.org/10.1002/ana.21291
Siderowf A, Newberg A, Chou KL, et al (2005) [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 64:1716–1720. https://doi.org/10.1212/01.WNL.0000161874.52302.5D
Soliman AM, Fathalla AM, Moustafa AA (2016) Dose-dependent neuroprotective effect of caffeine on a rotenone-induced rat model of parkinsonism: A histological study. Neuroscience Letters 623:63–70. https://doi.org/10.1016/j.neulet.2016.04.057
Takeuchi H, Yanagida T, Inden M, et al (2009) Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson’s disease models. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.21869
Targa ADS, Noseda ACD, Rodrigues LS, et al (2018) REM sleep deprivation and dopaminergic D2 receptors modulation increase recognition memory in an animal model of Parkinson’s disease. Behavioural Brain Research. https://doi.org/10.1016/j.bbr.2017.11.008
Xu K, Xu YH, Chen JF, Schwarzschild MA (2002) Caffeine’s neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neuroscience Letters 322:13–16. https://doi.org/10.1016/S0304-3940(02)00069-1
Yang F, Pedersen NL, Ye W, et al (2016) Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease. International Journal of Epidemiology dyw294. https://doi.org/10.1093/ije/dyw294
Yang J, Lv DJ, Li LX, et al (2019) Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson’s disease. NeuroToxicology 73:175–182. https://doi.org/10.1016/j.neuro.2019.02.008